MolecularMD Licenses LKB1 Marker for Lung Cancer Assay Development | GenomeWeb

NEW YORK (GenomeWeb News) – MolecularMD today said it has licensed a genetic marker for the development of diagnostic assays for non-small cell lung cancer.

The Portland, Ore.-based company has licensed the rights to commercialize the intellectual property around the biomarker LKB1 for diagnostic, prognostic, and predictive use, it said. The patent rights for LKB1 are jointly owned by the Dana-Farber Cancer Institute; the Massachusetts General Hospital; the University of North Carolina, Chapel Hill; and the University of Texas Southwestern Medical Center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.